Measuring clinical progression in mci and pre-mci populations: Enrichment and optimizing clinical outcomes over time

Alzheimer's Research and Therapy

Volumn 4, Issue , 2012, Pages

  Hendrix, Suzanne B ^a  

^a Pentara Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE ASSESSMENT SCALE; CLINICAL OUTCOME; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE MARKER; HUMAN; INTERMETHOD COMPARISON; MEASUREMENT ERROR; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; PARTIAL LEAST SQUARES REGRESSION; PATIENT IDENTIFICATION; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STANDARD; THERAPY EFFECT; VALIDATION STUDY;

EID: 84863443678     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt127     Document Type: Review

References (21)

1. Brooks LG, Loewenstein DA: Assessing the progression of mild cognitive impairment to Alzheimer?s disease: current trends and future directions. Alzheimers Res Ther 2010, 2:28.
2. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH: Toward defining the preclinical stages of Alzheimer?s disease: recommendations from the National Institute on Aging-Alzheimer?s Association workgroups on diagnostic guidelines for Alzheimer?s disease. Alzheimers Dement 2011, 7:280-292.
3. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ: The Alzheimer?s Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement 2012, 8 (1 Suppl):S1-S68.
4. Cummings J: Biomarkers in Alzheimer?s disease drug development. Alzheimers Dement 2011, 7:e13-44.
5. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer?s Disease Neuroimaging Initiative: Cerebrospinal fluid biomarker signature in Alzheimer?s disease neuroimaging initiative subjects. Ann Neurol 2009, 65:403-413.
6. Ho AJ, Hua X, Lee S, Leow AD, Yanovsky I, Gutman B, Dinov ID, Leporé N, Stein JL, Toga AW, Jack CR Jr., Bernstein MA, Reiman EM, Harvey DJ, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM; Alzheimer?s Disease Neuroimaging Initiative: Comparing 3 T and 1.5 T MRI for tracking Alzheimer?s disease progression with tensor-based morphometry. Hum Brain Mapp 2010, 31:499-514.
7. Hill D: Neuroimaging to assess safety and efficacy of AD therapies. Expert Opin Investig Drugs 2010, 19:23-26.
8. Llano DA, Laforet G, Devanarayan V: Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord 2010, 25:73-84.
9. Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR Jr., Aisen PS, Thal LJ: Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 2008, 70:191-199.
10. Jack CR Jr., Petersen RC, Xu YC, O?Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E: Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999, 52:1397-1407.
11. Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR Jr., Weiner MW; Alzheimer?s Disease Neuroimaging Initiative: MRI of hippocampal volume loss in early Alzheimer?s disease in relation to ApoE genotype and biomarkers. Brain 2009, 132 (Pt 4):1067-1077.
12. Holland D, Brewer JB, Hagler DJ, Fennema-Notestine C, Dale AM; Alzheimer?s Disease Neuroimaging Initiative: Subregional neuroanatomical change as a biomarker for Alzheimer?s disease. Proc Natl Acad Sci U S A 2009, 106:20954-20959.
13. Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, Kuo JH; Alzheimer?s Disease Neuroimaging Initiative: The Alzheimer?s Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement 2010, 6:257-264.
14. Husted JA, Cook RJ, Farewell VT, Gladman DD: Methods for assessing responsiveness: A critical review and recommendations. J Clin Epidemiol 2000, 53:459-468.
15. Coley N, Andrieu S, Jaros M, Weiner M, Cedarbaum J, Vellas B: Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer?s disease trials. Alzheimers Dement 2011, 7:602-610.e2.
16. Grober E, Ocepek-Welikson K, Teresi JA: The Free and Cued Selective Reminding Test: evidence of psychometric adequacy. Psychology Science Quarterly 2009, 51:266-282.
17. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer?s disease. Am J Psychiatry 1984, 141:1356-1364.
18. Hendrix SB: Requiring an amyloid- ß 1-42 biomarker may improve the efficiency of a study, and simulations may help in planning studies. Alzheimers Res Ther 2011, 3:10.
19. Shankle R, Atri A, Hendrix S: Improving measurement methodology to detect treatment effect in clinical trials. J Nutr Health Aging 2011, 15 (Suppl 1):s3. Abstract.
20. Cano SJ, Posner HB, Moline ML, Hurt SW, Swartz J, Hsu T, Hobart JC: The ADAS-cog in Alzheimer?s disease clinical trials: psychometric evaluation of the sum and its parts. J Neurol Neurosurg Psychiatry 2010, 81:1363-1368.
21. Donohue MC, Gamst AC, Thomas RG, Xu R, Beckett L, Petersen RC, Weiner MW, Aisen P, Alzheimer?s Disease Neuroimaging Initiative: The relative efficiency of time-To-Threshold and rate of change in longitudinal data. Contemporary Clin Trials 2011, 32:685-693.